Therapy News and Research

RSS

New Alzheimer's studies show advances against different treatment targets

Two studies related to experimental Alzheimer's therapies reported positive results today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago.

28 Jul 2008

How anti-depressants and cocaine interact with brain

In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.

28 Jul 2008

Hypnosis slows impacts of dementia and improves quality of life

A scientist at the University of Liverpool has found that hypnosis can slow down the impacts of dementia and improve quality of life for those living with the condition.

28 Jul 2008

Cocktail of drugs extends life of HIV patients

According to Canadian researchers a cocktail which is a combination of HIV drugs can give AIDS patients an average of 13 years additional life.

28 Jul 2008

Knowing means simplifying: gluten-free diet alone is enough to cure the bones of pediatric patients with celiac disease

Individuals affected by celiac disease (gluten intolerance) often present an altered calcium (Ca2+) metabolism that can cause osteopenia, a bone mass decrease due to the impaired adsorption of this mineral, which can lead to osteoporosis (in 35-85% of the cases).

27 Jul 2008

Lung inflammation from influenza and other infections could be turned off following new discovery

A new discovery could lead to treatments which turn off the inflammation in the lungs caused by influenza and other infections, according to a study published in the journal Nature Immunology.

27 Jul 2008

NIDDK publishes strategic plan for research into benign prostate

For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.

27 Jul 2008

Researchers disprove long-standing belief about HIV treatment

Researchers at Wake Forest University Baptist Medical Center have disproved a long-standing clinical belief that the hepatitis C virus slows or stunts the immune system's ability to restore itself after HIV patients are treated with a combination of drugs known as the 'cocktail.'

27 Jul 2008

Chemo and radiation after surgery prolongs life for pancreatic cancer patients

Pancreatic cancer patients treated with a combination of chemotherapy and radiation after surgery survive approximately six months longer than those receiving surgery alone, Johns Hopkins Kimmel Cancer Center scientists report.

24 Jul 2008

A dangerous precedent in HIV

Infection with HIV could quadruple in certain populations if people with HIV follow potentially misleading advice contained in a statement from the Swiss Federal Commission for HIV/AIDS, University of New South Wales (UNSW) research warns.

24 Jul 2008

Life expectancy of HIV patients increases

HIV-infected patients in high income countries are living some 13 years longer thanks to improvements in combination antiretroval therapy (cART), according to new research by the University of Bristol published in a HIV Special Issue of The Lancet today.

24 Jul 2008

Raltegravir drug combo works against highly resistant strain of HIV

A study involving an international team of scientists has discovered that a new drug when combined with other anti-HIV medications, is particularly effective against a highly resistant strain of the HIV virus.

24 Jul 2008

Statins appear to improve survival in kidney transplant recipients

For patients receiving kidney transplants, treatment with cholesterol-lowering "statin" drugs may lead to longer survival, reports a study in the November 2008 Journal of the American Society of Nephrology (JASN).

23 Jul 2008

New technique measures formation of clumps of proteins in protein-based pharmaceuticals

Scientists at the National Institute of Standards and Technology (NIST) have developed a technique to measure the formation of clumps of proteins in protein-based pharmaceuticals.

23 Jul 2008

Sorafenib extends life of advanced liver cancer patients

Researchers at Mount Sinai School of Medicine in New York have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug.

23 Jul 2008

Controlling plaque without toothpaste

Leeds Dental Institute, ranked the top school in the UK for dentistry is currently looking at new and better ways to improve dental treatment and take the fear factor out of the patient experience for good.

23 Jul 2008

Disease prevention programs cannot reduce costs in long term, columnist writes

The "formulation" that disease prevention programs can reduce health care costs in the long term "is a pleasant fantasy," syndicated columnist Froma Harrop writes in the Providence Journal.

23 Jul 2008

Researchers urge integrating TB into HIV care

In resource-limited settings where tuberculosis is a major cause of mortality among HIV patients and where a multidrug-resistant TB epidemic is emerging, researchers are pressing for approaches to integrate TB prevention and treatment into HIV care and treatment.

22 Jul 2008

New cartilage repair gel developed by University of Bradford

The University of Bradford's School of Engineering, Design and Technology and Advanced Gel Technology Ltd (AGT), a University spin out company, are developing a cartilage repair gel to improve the quality of life for people suffering with medical joint trouble such as osteoarthritis.

22 Jul 2008

Gilead initiates phase III trial of Elvitegravir

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.

22 Jul 2008